However, intervention with Panaxatriol can target paclitaxel-resistant breast cancer cells by blocking the activation of IRAK1/NF-κB and ERK signaling pathways, downregulating the expression of S100A7/9, inflammatory factors (IL-6, IL-8, CXCL1, CCL2), and cancer stem cell-related markers (OCT4, SOX2, NANOG, ALDH1, CD44), and restoring the sensitivity of breast cancer cells to paclitaxel [49]. The gene discussed is IRAK1; the disease is breast cancer.